

## Special Issue

# Advances in Pancreatic Ductal Adenocarcinoma Diagnosis and Treatment

### Message from the Guest Editor

Surgery remains the potentially curative treatment for pancreatic ductal adenocarcinoma (PDAC) without metastases, and en bloc resection with adequate surgical margins is associated with long-term survival. Venous invasion does not preclude patients from surgery because combined venous resection and reconstitution can be safely performed. In the age of molecularly-targeted drugs and immunotherapy, researchers put great efforts based on genomics and proteomics of PDAC into finding the best targeted therapy. Using our own many years of experience in the treatment of patients with PDAC and taking into account the latest scientific achievements, this Special Issue will discuss recent development in understanding genomic characteristics, early detection approach, innovations in the treatment of resectable, borderline resectable, locally advanced and metastatic PDAC, and in application of the therapeutics targeting new targets in pancreatic carcinoma.

---

### Guest Editor

Prof. Dr. Andrzej Deptała

Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland

---

### Deadline for manuscript submissions

closed (15 July 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/136557](https://mdpi.com/si/136557)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)